A Prospective Multicenter Sample Collection Study Using Non-invasive Methods to Investigate Mutation Burden in Non-lesional Facial Skin of Patients With a Hx of Skin Cancer

Inclusion Criteria: For the immunocompetent (non-SOTR) groups, a subject will be eligible if he or she: 1. Is at least 18 years of age; 2. Is willing to consent to non-invasive adhesive tape sampling and DNA mutation burden analysis; 3. Has a history of 10 or more basal cell carcinomas (BCCs) and at least a 10:1 ratio of BCC to other skin cancer types; or 4. Has a history of 5 or more squamous cell carcinomas (SCCs) and at least a 5:1 ratio of SCC to other skin cancer types; or 5. Has a history of 3 or more melanomas; or For the immunocompetent controls: 6. Has no history of skin cancer but is an age, birth sex, and Fitzpatrick phototype match (control) for an enrolled participant. For the SOTR groups, a subject will be eligible if he or she: 7. Is age 50-70; 8. Received a heart, lung, kidney, or liver transplant at least 5 years prior to study enrollment; or 9. Has a history of 5 or more keratinocyte carcinomas (BCC or SCC), or a history of 3 or more melanomas following organ transplantation. For the SOTR controls: 10. Is a transplant recipient age 50-70 with no more than 2 keratinocyte carcinomas. Exclusion Criteria: 1. Has applied certain topical medications (corticosteroids, alpha-hydroxy acids, retinoids, antibiotics, etc.) to the skin to be sampled within 30 days of beginning the study; 2. Has undergone field therapy for actinic keratoses (e.g. 5-fluorouracil) involving the skin to be sampled within the past 12 months; 3. Has a generalized skin disorder not related to skin cancer such as psoriasis, photosensitivity disorder, or eczematous dermatitis affecting the skin to be sampled; 4. Has a known allergy to latex rubber or tape adhesives; 5. Is currently participating in another investigational study, or has participated in another study within 30 days of initiating the current study; 6. Has applied a sunscreen, moisturizer, or other topical to the skin to be sampled that cannot be adequately removed and may therefore compromise sample collection; 7. Has clinical findings which the Investigator determines may put the subject at undue risk or may interfere with the study; 8. Has undergone phototherapy or used a tanning bed within 3 months of beginning the study; 9. Has used systemic retinoids, chemotherapeutics, or immunotherapy within 3 months of beginning the study; 10. Has used an immunosuppressive medication within 3 months of study initiation, such as azathioprine, cyclosporine, methotrexate, or any of the immunosuppressive biological therapies (TNF-inhibitors, etc.); 11. Is known or suspected to have a cancer predisposition syndrome (CPS), such as Gorlin syndrome / basal cell nevus syndrome, Xeroderma pigmentosum, Ferguson-Smith syndrome, Oculocutaneous albinism, Epidermolysis bullosa, Epidermodysplasia verruciformis, Fanconi anemia, Rombo syndrome, Bazex-Dupre-Christol syndrome, Bloom syndrome, Werner syndrome, Dyskeratosis congenita, Hereditary Breast and Ovarian Cancer (HBOC) syndrome, Lynch syndrome, etc.; 12. Is known or suspected to harbor a pathogenic germline mutation within one or more cancer predisposition genes, such as TP53, CDKN2A, NF1, BAP1, DICER1, FH, SDHD, VHL, etc.; and 13. Has a history of skin cancer that cannot be verified.